Disabling Cas9 by an anti-CRISPR DNA mimic

Jiyung Shin(Innovative Genomics Institute), Fuguo Jiang(QB3), Junjie Liu(Lawrence Berkeley National Laboratory), Nicolas Bray(Innovative Genomics Institute), Benjamin J. Rauch(QB3), Ron Baik(Innovative Genomics Institute), Eva Nogales(Howard Hughes Medical Institute), Joseph Bondy‐Denomy(QB3), Jacob E. Corn(Innovative Genomics Institute), Jennifer A. Doudna(QB3)
Science Advances
July 7, 2017
Cited by 364Open Access
Full Text

Abstract

CRISPR (clustered regularly interspaced short palindromic repeats)-Cas9 gene editing technology is derived from a microbial adaptive immune system, where bacteriophages are often the intended target. Natural inhibitors of CRISPR-Cas9 enable phages to evade immunity and show promise in controlling Cas9-mediated gene editing in human cells. However, the mechanism of CRISPR-Cas9 inhibition is not known, and the potential applications for Cas9 inhibitor proteins in mammalian cells have not been fully established. We show that the anti-CRISPR protein AcrIIA4 binds only to assembled Cas9-single-guide RNA (sgRNA) complexes and not to Cas9 protein alone. A 3.9 Å resolution cryo-electron microscopy structure of the Cas9-sgRNA-AcrIIA4 complex revealed that the surface of AcrIIA4 is highly acidic and binds with a 1:1 stoichiometry to a region of Cas9 that normally engages the DNA protospacer adjacent motif. Consistent with this binding mode, order-of-addition experiments showed that AcrIIA4 interferes with DNA recognition but has no effect on preformed Cas9-sgRNA-DNA complexes. Timed delivery of AcrIIA4 into human cells as either protein or expression plasmid allows on-target Cas9-mediated gene editing while reducing off-target edits. These results provide a mechanistic understanding of AcrIIA4 function and demonstrate that inhibitors can modulate the extent and outcomes of Cas9-mediated gene editing.


Related Papers

No related papers found

Powered by citation graph analysis